Characterization of Persistent COVID-19
持续性 COVID-19 的特征
基本信息
- 批准号:10744322
- 负责人:
- 金额:$ 86.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-10 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAccelerationAddressAmino AcidsAntibody titer measurementAntigensAntiviral AgentsAreaB cell therapyCD8-Positive T-LymphocytesCOVID-19COVID-19 mortalityCOVID-19 pandemicCOVID-19 pathogenesisCOVID-19 therapeuticsCharacteristicsChronicClinical ResearchCollaborationsDataDiseaseDrug resistanceEnrollmentEpidemiologyEvolutionGeneral PopulationGenesGeneticGoalsHealthHematologic NeoplasmsHematopoietic Stem Cell TransplantationImmuneImmune responseImmunocompetentImmunocompromised HostImmunologic Deficiency SyndromesImmunologicsImmunologyImmunosuppressionIncidenceIndividualInfectionLaboratoriesLong COVIDMethodsMonoclonal AntibodiesNatureOutcomeParticipantPathway interactionsPatientsPersonsPlayPopulationProductivityPublic HealthPublicationsRNARegimenResearch InfrastructureResearch PersonnelResistanceRiskRisk FactorsRisk ReductionRoleSARS-CoV-2 infectionSARS-CoV-2 variantSamplingSeverity of illnessSourceSymptomsT cell responseTherapeuticTranslational ResearchTreatment FailureVariantViralViral Drug ResistanceViral Load resultVirusVirus Diseasesantiviral drug developmentchronic infectionclinical careclinical riskcohortdeep sequencingexperiencehigh risk populationimmunosuppressedimprovednovel vaccinesrecruitresponsetranscriptome sequencingtransmission processtreatment responseviral RNAvirology
项目摘要
PROJECT SUMMARY
Immunosuppressed individuals are increasingly recognized as a focal point of the COVID-19 epidemic. They are
at increased risk of chronic COVID-19 infection, therapeutic treatment failure, severe disease and COVID-19
mortality. Evidence is also emerging that they may also be drivers of COVID-19 variant/subvariant emergence,
due to their risk of prolonged infection and accelerated viral evolution. However, the immune and viral
mechanisms by which chronic infection, viral evolution, and drug resistance occur in this population are poorly
understood. To improve health outcomes for this high-risk population and to reduce the risk of viral evolution and
drug resistance, there is an urgent need to address gaps in our understanding of which immune deficiencies
increase the risk of chronic COVID-19 infection and accelerated viral evolution. The primary goal of this proposal
is to determine the host and virologic characteristics that promote chronic viral infection and viral evolution. The
proposing investigators will an existing translational research infrastructure with experience recruiting cohorts
of immunosuppressed individuals with COVID-19 and broad expertise in clinical research, viral quantification,
viral culture, sequencing, and immunology. The results will provide critical new data about COVID-19
pathogenesis, variant evolution, therapeutic response, and inform the clinical care of immunosuppressed
populations. By deepening our understanding of the immune pathways of viral clearance, the results from this
proposal may also identify potential targets for the next generation of vaccines and therapeutics.
项目总结
免疫抑制的个人越来越被认为是新冠肺炎疫情的焦点。他们是
慢性新冠肺炎感染、治疗失败、严重疾病和新冠肺炎风险增加
死亡率。也有证据表明,它们也可能是新冠肺炎变异体/亚变种出现的驱动因素。
由于它们有长期感染和加速病毒进化的风险。然而,免疫和病毒
在这一人群中发生慢性感染、病毒进化和耐药性的机制很差。
明白了。改善这一高危人群的健康状况,降低病毒进化的风险
对于耐药性,迫切需要解决我们对哪些免疫缺陷的理解上的差距
增加慢性新冠肺炎感染的风险,加速病毒进化。这项提案的主要目标是
是确定促进慢性病毒感染和病毒进化的宿主和病毒学特征。这个
建议调查人员将建立一个现有的翻译研究基础设施,具有招募队列的经验
有新冠肺炎的免疫抑制患者,在临床研究、病毒定量、
病毒培养、测序和免疫学。研究结果将提供有关新冠肺炎的关键新数据
免疫抑制的发病机制、变异演变、治疗反应及临床护理
人口。通过加深我们对清除病毒的免疫途径的理解,这一结果
该提案还可能确定下一代疫苗和疗法的潜在目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amy K Barczak其他文献
Amy K Barczak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amy K Barczak', 18)}}的其他基金
Elucidating the path to type I IFNs in TB infection
阐明结核感染中 I 型干扰素的途径
- 批准号:
10592443 - 财政年份:2021
- 资助金额:
$ 86.87万 - 项目类别:
Elucidating the path to type I IFNs in TB infection
阐明结核感染中 I 型干扰素的途径
- 批准号:
10378549 - 财政年份:2021
- 资助金额:
$ 86.87万 - 项目类别:
A proteomic approach to understanding phagosome composition in TB infection
了解结核病感染中吞噬体组成的蛋白质组学方法
- 批准号:
9979082 - 财政年份:2020
- 资助金额:
$ 86.87万 - 项目类别:
A proteomic approach to understanding phagosome composition in TB infection
了解结核病感染中吞噬体组成的蛋白质组学方法
- 批准号:
10117183 - 财政年份:2020
- 资助金额:
$ 86.87万 - 项目类别:
Targeting MT1-MMP to inhibit pathologic inflammation in TB
靶向 MT1-MMP 抑制结核病病理炎症
- 批准号:
9808747 - 财政年份:2019
- 资助金额:
$ 86.87万 - 项目类别:
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.
结核分枝杆菌毒力细胞机制的化学遗传学方法。
- 批准号:
7892211 - 财政年份:2010
- 资助金额:
$ 86.87万 - 项目类别:
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.
结核分枝杆菌毒力细胞机制的化学遗传学方法。
- 批准号:
8517559 - 财政年份:2010
- 资助金额:
$ 86.87万 - 项目类别:
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.
结核分枝杆菌毒力细胞机制的化学遗传学方法。
- 批准号:
8704862 - 财政年份:2010
- 资助金额:
$ 86.87万 - 项目类别:
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.
结核分枝杆菌毒力细胞机制的化学遗传学方法。
- 批准号:
8150390 - 财政年份:2010
- 资助金额:
$ 86.87万 - 项目类别:
Chemical genetic approach to cellular mechanisms of M. tuberculosis virulence.
结核分枝杆菌毒力细胞机制的化学遗传学方法。
- 批准号:
8318274 - 财政年份:2010
- 资助金额:
$ 86.87万 - 项目类别:
相似海外基金
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
- 批准号:
2400967 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328975 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Continuing Grant
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
- 批准号:
NE/Y000080/1 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Research Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
- 批准号:
10112700 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328973 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328972 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332916 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332917 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328974 - 财政年份:2024
- 资助金额:
$ 86.87万 - 项目类别:
Continuing Grant
Radiation GRMHD with Non-Thermal Particle Acceleration: Next-Generation Models of Black Hole Accretion Flows and Jets
具有非热粒子加速的辐射 GRMHD:黑洞吸积流和喷流的下一代模型
- 批准号:
2307983 - 财政年份:2023
- 资助金额:
$ 86.87万 - 项目类别:
Standard Grant